A dose-response study of ramucirumab treatment in patients with gastric cancer/gastroesophageal junction adenocarcinoma: Primary results of 4 dosing regimens in the phase 2 trial I4T-MC-JVDB

被引：0
|
作者：
Ajani, J. A. [1 ]
Udrea, A. [2 ]
Sarosiek, T. [3 ]
Shenker, M. [4 ]
Morgan, C. [5 ]
Pikiel, J. [6 ]
Wojcik, E. [7 ]
Swinson, D. [8 ]
Joseph, M. [9 ]
Luft, A. [10 ]
Salek, T. [11 ]
Tournigand, C. [12 ]
Ferry, D. [13 ]
Zhang, Y. [13 ]
Long, A. [13 ]
Kuo, W-L. [13 ]
Gao, L. [13 ]
Kauh, J. [13 ]
Mansoor, W. [14 ]
机构：
[1] Univ Texas Houston, MD Anderson Canc Ctr, 1515 Holcombe Blvd, Houston, TX 77030 USA
[2] MedisProf SRL, Oncol, Cluj Napoca, Romania
[3] Magodent, Oncol, Warsaw, Poland
[4] Sf Nectarie SRL, Ctr Oncol, Craiova, Romania
[5] Velindre Canc Ctr, Oncol, Cardiff, S Glam, Wales
[6] COPERNICUS Podmiot Leczniczy, Oncol, Gdansk, Poland
[7] NZOZ Ctr Med HCP, Oncol, Poznan, Poland
[8] St James Univ Hosp, St Jamess Inst Oncol, Leeds, W Yorkshire, England
[9] New Cross Hosp, Deanesly Ctr, Wolverhampton, England
[10] Leningrad Reg Clin Hosp, Oncol, St Petersburg, Russia
[11] Narodny Onkol Ustav, Oncol, Bratislava, Slovakia
[12] CHU Henri Mondor, Oncol, Creteil, France
[13] Eli Lilly & Co, Oncol, Bridgewater, NJ USA
[14] NHS Fdn Trust, Christie Hosp, Manchester, Lancs, England
来源：
ANNALS OF ONCOLOGY | 2017年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
698P
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Zolbetuximab+mFOLFOX6 as First-Line (1L) treatment for patients (Pts) with Claudin-18.2+(CLDN18.2+) / HER2-Locally Advanced (LA) unresectable or metastatic Gastric or Gastroesophageal Junction (mG/GEJ) adenocarcinoma: primary results from Phase 3 SPOTLIGHT Study
    Lordick, F.
    Shitara, K.
    Bang, Y. -J
    Enzinger, P.
    Ilson, D.
    Shah, M. A.
    Van Cutsem, E.
    Xu, R. -H
    Aprile, G.
    Xu, J.
    Chao, J.
    Pazo-Cid, R.
    Kang, Y. K.
    Yang, J.
    Moran, D.
    Bhattacharya, P.
    Arozullah, A.
    Park, J. W.
    Ajani, J.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 115 - 116
  • [42] Primary analysis of a phase II single-arm trial of trastuzumab deruxtecan (T-DXd) in western patients (Pts) with HER2-positive (HER2+) unresectable or metastatic gastric or gastroesophageal junction (GEJ) cancer who progressed on or after a trastuzumab-containing regimen
    Van Cutsem, E.
    Di Bartolomeo, M.
    Smyth, E.
    Chau, I.
    Park, H.
    Siena, S.
    Lonardi, S.
    Wainberg, Z. A.
    Ajani, J. A.
    Chao, J.
    Seraj, J.
    Kawaguchi, Y.
    Qin, A.
    Singh, J.
    Meinhardt, G.
    Ku, G.
    ANNALS OF ONCOLOGY, 2021, 32 : S1332 - S1332
  • [43] Dose-escalated radiotherapy with PET/CT based treatment planning in combination with induction and concurrent chemotherapy in locally advanced (uT3/T4) squamous cell cancer of the esophagus: mature results of a phase I/II trial
    Poettgen, C.
    Gkika, E.
    Stahl, M.
    Abu Jawad, J.
    Gauler, T.
    Kasper, S.
    Trarbach, T.
    Herrmann, K.
    Lehmann, N.
    Joeckel, K-H
    Lax, H.
    Stuschke, M.
    RADIATION ONCOLOGY, 2021, 16 (01)
  • [44] Dose-escalated radiotherapy with PET/CT based treatment planning in combination with induction and concurrent chemotherapy in locally advanced (uT3/T4) squamous cell cancer of the esophagus: mature results of a phase I/II trial
    C. Pöttgen
    E. Gkika
    M. Stahl
    J. Abu Jawad
    T. Gauler
    S. Kasper
    T. Trarbach
    K. Herrmann
    N. Lehmann
    K.-H. Jöckel
    H. Lax
    M. Stuschke
    Radiation Oncology, 16
  • [45] Safety and efficacy from the phase 1 SURPASS trial of ADP-A2M4CD8, a next-generation Tcell receptor T-cell therapy, in patients with advanced esophageal, esophagogastric junction, or gastric cancer.
    Murphy, Mariela A. Blum
    Ajani, Jaffer A.
    Van Tine, Brian Andrew
    Clarke, Jeffrey Melson
    Butler, Marcus O.
    Lawrence, Donald P.
    Johnson, Melissa Lynne
    Cervantes, Andres
    Moreno, Victor
    Hong, David S.
    Brophy, Francine Elizabeth
    Navenot, Jean-Marc
    Lin, Quan
    Saro, Jose
    Norry, Elliot
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 349 - 349
  • [46] Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial
    Al-Batran, Salah-Eddin
    Hofheinz, Ralf D.
    Pauligk, Claudia
    Kopp, Hans-Georg
    Haag, Georg Martin
    Luley, Kim Barbara
    Meiler, Johannes
    Homann, Nils
    Lorenzen, Sylvie
    Schmalenberg, Harald
    Probst, Stephan
    Koenigsmann, Michael
    Egger, Matthias
    Prasnikar, Nicole
    Caca, Karel
    Trojan, Joerg
    Martens, Uwe M.
    Block, Andreas
    Fischbach, Wolfgang
    Mahlberg, Rolf
    Clemens, Michael
    Illerhaus, Gerald
    Zirlik, Katja
    Behringer, Dirk M.
    Schmiegel, Wolff
    Pohl, Michael
    Heike, Michael
    Ronellenfitsch, Ulrich
    Schuler, Martin
    Bechstein, Wolf O.
    Koenigsrainer, Alfred
    Gaiser, Timo
    Schirmacher, Peter
    Hozaeel, Wael
    Reichart, Alexander
    Goetze, Thorsten O.
    Sievert, Mark
    Jaeger, Elke
    Moenig, Stefan
    Tannapfel, Andrea
    LANCET ONCOLOGY, 2016, 17 (12): : 1697 - 1708
  • [47] Beamion BCGC-1: A phase Ib/II trial of the HER2-selective tyrosine kinase inhibitor (TKI) zongertinib (BI 1810631) + trastuzumab deruxtecan (T-DXd) or trastuzumab emtansine (T-DM1) for patients with metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC).
    Nakayama, Izuma
    Berz, David
    Yazgili, Sila Aykut
    Erzen, Damijan
    Shitara, Kohei
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : TPS509 - TPS509
  • [48] Phase I dose-escalation study on irinotecan, cisplatin, and S-1 combination in chemotherapy-naive patients with HER2-negative advanced gastric cancer (HERBIS-4B, OGSG 1106)
    Yukami, Hiroki
    Kawakami, Hisato
    Yamaguchi, Toshifumi
    Sakai, Daisuke
    Shimokawa, Toshio
    Kurokawa, Yukinori
    Goto, Masahiro
    Satoh, Taroh
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2023, 28 (09) : 1176 - 1182
  • [49] Zolbetuximab+mFOLFOX6 as first-line (1L) treatment for patients (pts) withclaudin-18.2+(CLDN18.2+) / HER22 locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: Primary results from phase 3 SPOTLIGHT study
    Shitara, Kohei
    Lordick, Florian
    Bang, Yung-Jue
    Enzinger, Peter C.
    Ilson, David H.
    Shah, Manish A.
    Van Cutsem, Eric
    Xu, Rui-hua
    Aprile, Giuseppe
    Xu, Jianming
    Chao, Joseph
    Pazo-Cid, Roberto
    Kang, Yoon-Koo
    Yang, Jianning
    Moran, Diarmuid Martin
    Bhattacharya, Pranob P.
    Arozullah, Ahsan
    Park, Jung Wook
    Ajani, Jaffer A.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : LBA292 - LBA292
  • [50] Nivolumab plus chemotherapy in patients with HER2-negative, previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: 3-year follow-up of the ATTRACTION-4 randomized, double-blind, placebo-controlled, phase 3 trial
    Boku, Narikazu
    Omori, Takeshi
    Shitara, Kohei
    Sakuramoto, Shinichi
    Yamaguchi, Kensei
    Kato, Ken
    Kadowaki, Shigenori
    Tsuji, Kunihiro
    Ryu, Min-Hee
    Oh, Do-Youn
    Oh, Sang Cheul
    Rha, Sun Young
    Lee, Keun-Wook
    Chung, Ik-Joo
    Sym, Sun Jin
    Chen, Li-Tzong
    Chen, Jen-Shi
    Bai, Li-Yuan
    Nakada, Takashi
    Hagihara, Shunsuke
    Makino, Reina
    Nishiyama, Eiji
    Kang, Yoon-Koo
    GASTRIC CANCER, 2024, 27 (06) : 1287 - 1301
12345